

[View in browser](#)

## March 2020 ITOG Quarterly Update E-Newsletter

-

-

### Executive Committee

**Manisha H. Shah, MD, Chair**

The Ohio State University

**Sareh Parangi, MD, Secretary**

Harvard Medical School

**Eric Sherman, MD Chair, Protocol Committee**

Memorial Sloan-Kettering Cancer Center

**Dwight Vicks III MBA, Treasurer**

President, Vicks, Inc.

---

### Board of Directors

**Keith C. Bible, M.D., Ph.D.**

Mayo Clinic (Rochester)

**Naifa Busaidy, MD**

MD Anderson Cancer Center

**Maria Cabanillas, MD**

MD Anderson Cancer Center

**James Fagin, MD**

Memorial Sloan-Kettering

**Andrew Gianoukakis, MD**

University of California, Los Angeles

**Elizabeth Grubbs, MD**

MD Anderson Cancer Center

**Bryan Haugen, MD**

University of Colorado, Health Sciences Center

**Alan Ho MD, PhD**

Memorial Sloan-Kettering

**Sophie Leboulleux**

Gustave Roussy

**Gregory Randolph,**

MD Massachusetts Eye and Ear Infirmary

**Bruce G. Robinson, MD**

University of Sydney

**Julie Ann Sosa, M.D.**

University of California, San Francisco

**March 30 2020**

**Dear Friends:**

Happy Spring 2020! I sincerely hope that you and your family/friends and community are staying healthy in these unique times of COVID-19 pandemic.

As I near towards finishing two years of my three-year term as a Chair of ITOG, I would like to express deep gratitude to all of you for believing in me and supporting me in this role. I cannot thank each of ITOG Board of Directors (BOD) enough for their strong work, wisdom and passion in leading ITOG during this time. Similarly, I am blown away by seeing lot of energy and interest by various committee and task force members and leaders for their work for ITOG so big thanks to all of them.

We all are very disappointed with cancelation of the 2020 Annual ITOG Meeting in Paris given the pandemic, however, I promise you on 'making up' for this lost educational and networking opportunity in coming year. Please join me in thanking Sophie Leboulleux, Martin Schlumberger and Antoine Crouan of Gustave Roussy for their hard work in planning an excellent international meeting and task force leaders to collaborate with the host team on preparing a great scientific program. We will be sure to build upon it for our 2021 Annual ITOG Meeting.

Congratulations to protocol chairs and all participating site PIs and teams for achieving important milestone of meeting target accrual goals for following ITOG trials:

1. RU241306I, Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination with Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers (Protocol Chair/co-chair: Drs. Alan Ho and Mabel Ryder)
2. ACCRU-ITOG-1504, Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study (Protocol Chair/co-chair: Drs. Bryan Haugen and Lori Wirth)

Finally, a big shout out to all the members and leaders of Website & Communication Committee for their incredible work that led to launching of redesigned ITOG website ([www.itog.org](http://www.itog.org)) in January 2020 and working to develop "Virtual Central Office".

Wishing you all the best,

Manisha Shah, MD  
ITOG Chair

## **2020 Annual Meeting Update**

**On behalf of the ITOG Board of Directors and**

**2020 Annual Meeting Host Committee**

Over last 10 days, ITOG Executive committee and Board of Directors (BOD) have had several discussions about the ITOG Annual Meeting in Paris, France May 13-15, 2020 in light of fast-moving COVID-19 Pandemic. Thank you to

those of you who had chance to provide input. The health and safety of our members, guests and patients is our top priority. After considering several options, the **BOD has unanimously voted to CANCEL the ITOG Annual Meeting in Paris, France May 13-15, 2020.**

[Read More](#)

## [ITOG Active Clinical Trials](#)

### **ITOG Selumetinib Trial Achieves Accrual Goal!**

Congratulations to Principal Investigator: Alan Ho, MD at Memorial Sloan-Kettering Cancer Center and his team for achieving accrual goal of 60 for the [Selumetinib plus RAI for RAI-Avid Thyroid Cancer](#).

---

#### [ACCRU/ITOG 1504 Combination Immunotherapy with Multikinase Inhibitor \(MKI\) in Progressive, Radioreistant Differentiated Thyroid Cancers](#)

Accrual Status: Accruing  
Accrual Goal: 60  
Current Accrual: 56

PI: [Bryan Haugen, MD](#)

University of Colorado Cancer Center

#### [Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer \(LIBRETTO- 001\)](#)

Accrual Status: Accruing

#### [Selumetinib plus RAI for RAI-Avid Thyroid Cancers](#)

Accrual Status: Closed to Accrual  
Accrual Goal: 60  
Current Accrual: 60

PI: [Alan Ho, MD](#), Memorial Sloan-Kettering Cancer Center

#### [Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab \(CaboNivolpi\) for Advanced Differentiated Thyroid Cancer](#)

Accrual Status: Accruing

[Bhavana Konda, MD, MPH](#)

Ohio State University

**Dabrafenib, Trametinib, and IMRT  
in Treating Patients With BRAF  
Mutated Anaplastic Thyroid Cancer**

Accrual Status:

[PI: Manisha Shah, MD](#)

Ohio State University

---

## ITOG TOP NEWS

### **LOXO-292 demonstrates promising anti-tumor activity in RET-altered thyroid cancer**

ITOG member Dr. Lori Wirth recently presented progress on a Phase 1/2 study of LOXO-292 at the European Society for Medical Oncology (ESMO) Annual Congress in Barcelona, Spain. This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LOXO-292 administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

[Read More](#)

---

### **ITOG Robert F. Gagel Discovery Award Recipient Carmelo Nucera, MD**

Please join us in congratulating the 2019  
Robert F. Gagel ITOG Discovery

[Read More](#)

Award Recipient, Carmelo Nucera, MD for his submission “Engineering a new mouse model of a thyroid-specific lincRNA in BRAFV600E papillary thyroid carcinoma.”

---

## **ITOG/ATA Collaboration**

Jochen Lorch's second article was published in the December 2019 American Thyroid Association (ATA) Publication Clinical Thyroidology - The long road ahead: A phase 2 study of Pembrolizumab combined with Chemoradiotherapy as initial treatment for Anaplastic Thyroid Cancer

[Read More](#)

---

## **ITOG MEMBERS CORNER**

### **ITOG Virtual Central Office**

The Website and Communications Committee working to increase our global presence and provide that provides online engagement. The Administrative Team Judy Dallas, Brenda Mitchell, Noelle Paffett-Lugassy, and Danielle Fulgoni, working develop a “Virtual Central Office” to provide, support to ITOG Leadership. As well as consistency, access, excellent customer service, to our members, partners, donors, and patients.

These uncertain times, highlight the significance of collaboration and information sharing; and we are committed to doing whatever we can to support our members. Therefore, in addition to our redesigned Website launch in January, we are excited to debut the ITOG Quarterly E-Newsletter, issued March, June, September, and December. We will highlight the latest news, clinical trials, and updates in our Mission to “Catalyze a Cure for Thyroid Cancer.”

---

### **ITOG Membership Dues Invoicing Issue Update**

In February 2020, Membership dues invoices were sent reflecting the incorrect expiration date of December 2020. The correct expiration date should have been December 2019 as we are still collecting 2019 dues.

The billing process was delayed due to the transition of the new membership management system.

We are reviewing all records, and will send updated invoices in April. Our goal is to bring all memberships current by June 30, 2020. If you have already brought your 2019 and 2020 membership current, thank you for your payment.

## Credit Cards Now

### Accepted Online

We are proud to announce that ITOG website now accepts credit cards in addition to PayPal for membership dues and donations.



---

## Have You Updated your ITOG Membership Profile?

In January 2020, we launched our updated website and introduced our new "Membership Platform" and invite you to join us! Please follow this link to log-in and update your profile.

As a member, you will find access to our Member Directory, Community Forum, and Members Only information, including ITOG Clinical Trial Updates.

ITOG Members are making an impact on our mission to "Catalyze a Cure for Thyroid Cancer" and you can read about them here.

We also encourage you to share your news with our members.

[Log In](#)

---

## ITOG and WebEx

As an International organization we are currently using WebEx as our web-based conferencing solution. Its benefits include easy to use, easily share documents, presentations, or applications and cost effective.

We do not have an International Dial-in number, and request that our International Members utilize the Web, to join our calls by following these steps:

1. Open Outlook Invite
2. Enter
3. Click "Join WebEx meeting"
4. Connect via your computers microphones

5. Or Select Call Me – select your Country Code; enter cell or landline number.

---

## The Best Resource for ITOG News is YOU!

We need your help to generate current, engaging content for the ITOG website. To facilitate this process, you can simply email a quick draft mailto:[itog.npl@gmail.com](mailto:itog.npl@gmail.com) or idea to our in-house scientific writer, who will edit or write copy that will be reviewed and published to our site.

Please share the following for publication on the ITOG website:

- Thyroid Cancer News and Breakthroughs
- Clinical Trials
- Publications, Presentations
- Grants
- Awards and Acknowledgements
- Promotions and Retirements
- Meetings and Events
- Industry News
- Fundraising
- Patient Stories
- ITOG Announcements and Updates
- Photographs

**Click Below to Submit News Item**

[Submit News Item](#)

---

<http://itog.org/members/EmailOptPreferences.aspx?id=60158626&e=judydallas@gmail.com&h=356403d864e3c6a0a781c5982a94053a14a12979>